Abstract: Childhood apraxia of speech (CAS) is a rare disorder of childhood that can leave a watermark of the impacts throughout the lifetime. Since being first described in the 1950s, aetiological insights have been limited. At a neurobiological level, clinical MRI scans fail to reveal overt neural anomalies in individual cases with CAS, although quantitative MRI methods have revealed subtle brain anomalies at a group level. Dramatic insights, however, occurred in the past decade from the discovery of genetic pathways underlying the phenotype. Several single genes and copy number-variant conditions are now associated with CAS either in relative isolation, as in the case of FOXP2 variants, or most typically in association with other neurodevelopmental conditions, such as epilepsy, intellectual disability, motor impairment and autism. CAS requires careful differential diagnosis from other childhood speech disorders, but when a severe and persistent diagnosis is confirmed, a genetic aetiology should increasingly be pursued.
Symptomatology and Diagnosis of CAS
CAS is a complex disorder, defined as a higher-order motor system deficit of motor planning and programming. More specifically, motor planning involves transforming abstract sound representations into speech-motor goals or commands, and it also involves further specifying the specific movement or acoustic parameters within each articulator for speech production. 7 There is general consensus regarding three core diagnostic features for CAS: (i) inconsistent speech errors (e.g. producing the same syllable or word differently across repetitions of the same word, such as 'opsa', 'upal', 'pital' for hospital); (ii) lengthened and disrupted co-articulatory transitions (e.g. oral groping during speech; difficulty sequencing sounds and syllables, including frequent omissions of sounds in some cases; marked vowel errors; or hypernasality due to poor on-line planning and programming of velum (palatal) movements for denoting oral/nasal contrasts); and (iii) inappropriate prosody (e.g. disrupted rhythm and intonation of speech, such as placing stress on a typically unstressed syllable of a word or placing equal stress across all syllables). 8 The crux of a CAS diagnosis is based on differentiating the speech presentation from other developmental speech impairments of articulation disorder, phonological disorder, stuttering or dysarthria (Table 1) . In 'pure' or isolated idiopathic CAS, children reportedly demonstrate the apraxic speech deficit in isolation from any co-occurring neurodevelopmental condition. Isolated CAS is also unrelated to orofacial structural impairments associated with structural articulation deficits, such as cleft lip or palate, submucous cleft palate, macroglossia or a malocclusion (Table 1) . Furthermore, isolated CAS is also distinct from dysarthria, that is, disorder of the central or peripheral nervous system affecting physical strength, tone or range of movement, affecting speech production (Table 1) . A thorough oral structural and functional examination will help identify the presence of oralstructural deficits affecting articulation and will also indicate the presence of a disrupted tone or control of neuromuscular movement indicative of dysarthria. A clinical magnetic resonance imaging (MRI) to check for neurological lesions may also be indicated if dysarthria is suspected; children with isolated CAS do not show lesions on routine MRI. However, isolated CAS is rare, and in many cases, children demonstrate one or more of these other developmental speech disorders articulation, phonology dysarthria or even stuttering, alongside CAS. [13] [14] [15] [16] Final important considerations of a CAS diagnosis include that: (i) features of CAS tend to be less severe with age, with sounds and syllables being co-articulated more clearly and efficiently (although altered prosody remains a hallmark); (ii) there is heterogeneity in the severity and specific type of symptomatology across the population; and (iii) it is more challenging to provide a reliable CAS diagnosis when it co-occurs with other neurodevelopmental disorders, particularly in children who are largely nonverbal at older age ranges, such as often occurs in autism or global developmental delay.
Embracing Complexity in the CAS Phenotype
Cases with isolated idiopathic CAS have received the most research interest, arguably limiting our understanding of cases with more complex comorbid profiles. Most recently, however, the identification of single genes or related biological pathways associated with CAS has encouraged the application of broader phenotyping approaches in the field. These phenotyping approaches encompass not only speech symptomatology but also other neuropsychological, neurobiological, morphological, behavioural and medical symptoms, embracing the heterogeneity and comorbidity that is more representative of the broader CAS population.
Neurobiology of CAS
In terms of neurological involvement, routine clinical MRI scans are not currently sensitive enough to identify neural anomalies or correlates for individual children with isolated idiopathic CAS, even when the phenotype or clinical presentation is severe. A handful of reports exist on overt clinical MRI findings in children with known causes of CAS that occur with medical or neurodevelopmental comorbidities, such as galactosaemia due to disruption to GALT1, creatine transporter deficits and rolandic epilepsy. 17 To date, however, the most comprehensive quantitative MRI work in this area has been conducted in CAS associated with FOXP2 mutation. [18] [19] [20] [21] [22] [23] These studies suggest the phenotype is associated with a broad neural network but is most commonly characterised by anomalies of the inferior frontal cortices, rolandic cortices, basal ganglia and cerebellum. 17, 21 There is some variability in the neural phenotype, however, even in these cases with similar genotypes. 21 
Genetic Bases of CAS
The discovery that variants of FOXP2 were associated with a rare and monogenic form of CAS 24 catalysed the study of further genes for speech and language disorders. More than 15 years after the FOXP2 discovery, microarray and next-generation technologies now enable rapid and relatively cost-efficient genetic testing and have led to a proliferation of further discoveries of gene pathways associated with CAS. [13] [14] [15] [16] 25, 26 To highlight the rapidly growing aetiological knowledge in this field, and the presence of significant neurodevelopmental comorbidity for many cases with CAS, we will illustrate genotypephenotype associations for a handful of single-gene variant and copy number-variant conditions associated with CAS (Table 2) . It was beyond the scope of this article to provide an exhaustive summary of all neurogenetic syndromes, copy number-variant conditions or even chromosomal rearrangements associated with CAS; however, CAS has been associated with conditions such as Floating-Harbor syndrome, 27 Cri du chat syndrome, 28 galactosaemia, 29 based on reported cases. 34 Individuals with intragenic mutations disturbing FOXP2 may be categorised as having 'FOXP2-only'-related speech and language disorders, whereas cases with FOXP2 disruption via translocation, deletion or other complex variants, such as pericentromeric inversion or uniparental disomy, may be referred to as 'FOXP2-plus'-related speech and language disorders. 34 Cases with the underlying genetic alteration of 'FOXP2-only' typically have a preserved performance intelligence quotient compared to verbal intelligence quotient, appropriate social abilities and typical fine and gross motor skills alongside CAS, although mild cognitive impairment, mild motor impairments, autistic features (but not a formal autism spectrum disorder (ASD) diagnosis) and even mild dysmorphology (e.g. narrow palpebral fissures, mild finger pads, horizontal eyebrows, large ears) have recently been reported in some cases with FOXP2-only mutations. 32, 34 By contrast, individuals with FOXP2-plus genetic aberrations are more likely to have global developmental and behavioural issues with oral-motor deficits, global developmental delay and ASD alongside CAS. 34 These additional phenotypes may relate to disruptions of other genes neighbouring FOXP2 in that region of chromosome 7.
GRIN2A
The identification of a role for GRIN2A in CAS has a long history, beginning 60 years ago with the discovery of epilepsyassociated speech and language disorders or 'aphasias'. 35 Further clinical enquiry into children with epilepsy since this time has revealed a broad spectrum of epilepsy aphasias, which represents an association between epilepsy, speech (including CAS) and language disorders and the electroencephalography (EEG) signature of centro-temporal spikes. 36 In recent years, mutations or very small deletions in GRIN2A have been identified in patients with focal epilepsy and speech and language dysfunction. 37 Variable epilepsy and linguistic phenotypes may be associated with the GRIN2A genotype, but in relation to speech, CAS, dysarthria and oral-motor impairments have been consistently reported across families regardless of the associated form of epilepsy. 38 The speech phenotype may also occur in the absence of a seizure disorder, suggesting an important role for GRIN2A in speech-motor function or CAS 38 and not only in the epilepsy aphasias.
SETBP1
Germline de novo mutations in SETBP1 have been identified as the cause of Schinzel-Giedion syndrome, a rare and severe developmental disorder of seizures, midface hypoplasia, cardiac defects and skeletal abnormalities, with a link to somatic events seen in myeloid malignancies. 39 Yet recent reports of germline chromosomal deletions and truncating mutations in SETBP1 show that loss-of-function mutations cause a markedly different and less severe phenotype, with impaired expressive speech, relatively intact receptive language abilities, decreased fine motor skills, hyperactivity/ADHD, autistic traits and subtle dysmorphism. 40, 41 Most recently, the phenotype was expanded to specify two cases 
16p11.2 deletion + subtle + + + − + + + + mild †Phenotypic heterogeneity is common; hence, this table is intended to provide a representative summary of features often seen in association with the genotype in question. −, Feature is typically absent; +, feature is typically present; ?, unknown; ADHD, attention deficit hyperactivity disorder; ASD, autism spectrum disorder diagnosis or symptoms; mild-mod, a range between mild and moderate; mod, moderate.
with CAS with a SETBP1 frameshift mutation and de novo LoF mutation, respectively.
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BCL11A and 2p15p16.1 microdeletion
Microdeletions of BCL11A have been reported in association with CAS, dysarthria, hypotonia and general oral and gross motor dyspraxia alongside the usual constellation of features associated with the 2p15p16.1 microdeletion syndrome, 14, 42, 43 namely, a broad intellectual disability (ID) profile with concomitant poor expressive language, growth retardation, ASD, craniofacial and skeletal dysmorphic traits, internal organ defects, abnormal muscle tone and gross motor delays. 46 identified nine participants across six families with rare deletions at 12p13.33. ELKS/ERC1 was the only gene consistently deleted across affected family members; hence, the authors hypothesised that this gene was key to the expression of the phenotype. Delayed first words (36-42 months), delayed walking and prominent ear lobes were common features. 46 Five of the nine participants were reported to have CAS. Language and reading difficulties were reported in some. The participants also had a broader profile of neurodevelopmental disorders beyond speech and language, including intellectual impairment (5/9), psychiatric manifestations (5/9), behavioural difficulties (7/9), ADHD (6/9) and ASD (2/9). 46 Overall, it appears that deletions of 12p13.33 may be responsible for variable phenotypes, including CAS, associated with a broader neurobehavioural syndrome.
16p11.2 deletion
The 16p11.2 deletion represents one of the most well-studied CNVs in neurodevelopmental disorders. These deletions are relatively common, occurring in around 1 per 5000 individuals and occurring in either de novo or inherited forms. 47 Moderate ID, ASD, poor cognitive and language ability (as great as 2 standard deviation below familial non-carriers), epilepsy, macrocephaly (apparent by age 2 years), brain abnormalities such as Chiari type 1 malformations or cerebellar ectopia and obesity are associated with 16p11.2 deletion. 47 Several studies have also confirmed the high penetrance of CAS in children with 16p11.2 deletions. 13, 48 Other speech profiles have also been reported in 16p11.2 deletion in addition to CAS, including articulation and phonological disorders, dysarthria, minimal verbal output and even typical speech in some. 13 
Conclusions
The paediatric evaluation of a child with CAS should clarify whether the speech disorder is consistent with a diagnosis of CAS and whether there are coexisting problems with speech (e.g. dysarthria). The clinician should look for evidence of comorbid neurodevelopmental disorders such as ID or autism. An oral examination should be performed as well as a neurological examination. In children who have abnormal neurological findings or in whom there is evidence of dysarthria, an MRI of the brain could be considered. In most children, a comparative genomic hybridisation microarray should be performed. Furthermore, if the child has epilepsy or if they have a speech disorder that shows considerable fluctuation, then a sleep EEG should be considered (abnormal in GRIN2A-associated CAS). Evidence is increasingly suggesting that CAS is a genetic disorder, yet the genetic landscape is complex and not fully understood. Mutations of FOXP2 only have been associated with a relatively homogeneous phenotype of CAS and language disorder in the absence of ID, but this has been the only candidate gene to date to show a selectivity of this kind. Other genotypes associated with CAS, to date, generally lead to broader ID syndromes (e.g. BCL11A, KANSL1) and/or significant medical comorbidities such as epilepsy (e.g. GRIN2A) or autism (16p11.2 deletion), where CAS may occur as part of the broader spectrum of the condition.
Clinical implications for refining the aetiology of CAS are clearly significant in terms of personalised medicine, with the prospect of optimised diagnosis, genetic and prognostic counselling and targeted therapeutics. For the moment, where CAS appears persistent and severe, a genetic aetiology should be increasingly pursued.
